Sonnet BioTherapeutics Analyst Ratings
BenzingaFeb 15 12:33 ET
BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
TipRanksJan 7 05:47 ET
Sonnet BioTherapeutics Holdings (SONN) Gets a Buy From BTIG
TipRanksJan 2 09:49 ET
Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7
BenzingaNov 27, 2023 09:00 ET
Sonnet BioTherapeutics Analyst Ratings
BenzingaNov 27, 2023 08:59 ET
Sonnet BioTherapeutics Analyst Ratings
BenzingaAug 23, 2023 04:36 ET
Sonnet BioTherapeutics Analyst Ratings
BenzingaAug 16, 2023 10:22 ET
Chardan Capital Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
TipRanksAug 16, 2023 09:35 ET
Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating
MT NewswiresAug 16, 2023 09:32 ET
Sonnet BioTherapeutics Holdings (SONN) Receives a Buy From EF Hutton
TipRanksJun 26, 2023 12:25 ET
EF Hutton Reiterates Buy on Sonnet BioTherapeutics, Maintains $6.7 Price Target
BenzingaJun 26, 2023 09:13 ET
Chardan Lowers Price Target on Sonnet BioTherapeutics to $14 From $17, Keeps Buy Rating
MT NewswiresMay 11, 2023 06:23 ET
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $14
BenzingaMay 11, 2023 05:21 ET
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $17
BenzingaApr 19, 2023 06:23 ET
EF Hutton Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
TipRanksFeb 15, 2023 07:35 ET
Sonnet BioTherapeutics Analyst Ratings
Benzinga Analyst RatingsFeb 15, 2023 04:43 ET
EF Hutton Reiterates Buy on Sonnet BioTherapeutics, Maintains $6.7 Price Target
Benzinga Real-time NewsFeb 15, 2023 04:42 ET
Sonnet BioTherapeutics Analyst Ratings
Benzinga Analyst RatingsDec 19, 2022 07:12 ET
Chardan Adjusts Sonnet BioTherapeutics Holdings Price Target to $22 From $2, Maintains Buy Rating
MT NewswiresSep 22, 2022 09:37 ET
Sonnet BioTherapeutics Analyst Ratings
Benzinga Analyst RatingsSep 22, 2022 09:02 ET
No Data
No Data